Ascendis Pharma A/S (A1SN34)
B3 Stock Exchange · Brazil · prices in BRL · close of 26 Oct 2026
Key indicators
| Last close | BRL 88.40 |
|---|---|
| 52-week range | 70.00 – 94.05 |
| Return, 1 month / 3 months | +14.4% / −4.1% |
| Return, 1 year / 3 years | +23.7% / +196.4% |
| Trend | Uptrend |
| RSI (14) | 74 |
| Volatility (1 year) | 31.7% |
| Worst drawdown (1 year) | -19.5% |
| Average daily value traded | 0.00M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ascendis Pharma is a biopharmaceutical company based in Copenhagen, Denmark, that develops long-acting medicines by attaching a drug to a carrier molecule so it releases slowly in the body. Its products treat hormone-related conditions, including growth hormone deficiency in children and low parathyroid hormone in adults. The company serves patients and healthcare providers through specialty medicine markets, and it also runs a commercial operation alongside its research and development work.
Ascendis Pharma A/S is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code A1SN34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ascendis Pharma A/S (A1SN34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 88.40 on 26 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 545 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 23.7% and over the last three months it fell 4.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.7% | ||
| From 52-week high | -6.0% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -4.1% | ||
| 6-month return | 16.2% | ||
| 12-month return, skipping the last month | 8.1% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 31.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.5% | ||
| Liquidity | 19 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M BRL | ||
| Zero-volume days | 70.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +15.6% |
|---|---|
| 1 month | +14.4% |
| 3 months | −4.1% |
| 6 months | +16.2% |
| 1 year | +23.7% |
| 3 years | +196.4% |
| 5 years | +60.1% |
Signals
| 50-day / 200-day average | 83.81 / 80.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.34 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.